182 related articles for article (PubMed ID: 36696581)
21. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
[TBL] [Abstract][Full Text] [Related]
22. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos D; Tan DS; Jones RL; Judson IR
Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
25. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Molhoek KR; Shada AL; Smolkin M; Chowbina S; Papin J; Brautigan DL; Slingluff CL
Melanoma Res; 2011 Aug; 21(4):274-84. PubMed ID: 21654344
[TBL] [Abstract][Full Text] [Related]
27. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.
Jaquish DV; Yu PT; Shields DJ; French RP; Maruyama KP; Niessen S; Hoover H; A Cheresh D; Cravatt B; Lowy AM
Carcinogenesis; 2011 Aug; 32(8):1151-6. PubMed ID: 21565828
[TBL] [Abstract][Full Text] [Related]
28. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma.
Aslam MI; Hettmer S; Abraham J; Latocha D; Soundararajan A; Huang ET; Goros MW; Michalek JE; Wang S; Mansoor A; Druker BJ; Wagers AJ; Tyner JW; Keller C
Mol Cancer Res; 2013 Nov; 11(11):1303-13. PubMed ID: 23928059
[TBL] [Abstract][Full Text] [Related]
29. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
[TBL] [Abstract][Full Text] [Related]
30. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.
Montero JC; Seoane S; Pandiella A
Cell Signal; 2013 Nov; 25(11):2281-9. PubMed ID: 23899556
[TBL] [Abstract][Full Text] [Related]
32. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
33. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Wojtalla A; Salm F; Christiansen DG; Cremona T; Cwiek P; Shalaby T; Gross N; Grotzer MA; Arcaro A
PLoS One; 2012; 7(10):e47109. PubMed ID: 23056595
[TBL] [Abstract][Full Text] [Related]
34. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between the insulin-like growth factor 1 receptor signaling pathway and the resistance of nasopharyngeal carcinoma to cetuximab].
Zuo Q; Luo RC
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):575-9. PubMed ID: 21122407
[TBL] [Abstract][Full Text] [Related]
37. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
38. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
[TBL] [Abstract][Full Text] [Related]
39. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
[No Abstract] [Full Text] [Related]
40. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]